Experimental infection of adultswith recombinantwild-type human metapneumovirus

Journal of Infectious Diseases

Volumn 208, Issue 10, 2013, Pages 1669-1678

  Talaat, Kawsar R ^a   Karron, Ruth A ^a   Thumar, Bhagvanji ^a   McMahon, Bridget A ^c   Schmidt, Alexander C ^b   Collins, Peter L ^b   Buchholz, Ursula J ^b  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c GSK   (Belgium)

Author keywords

Challenge; HMPV; Human metapneumovirus

Indexed keywords

CYTOKINE; HUMAN METAPNEUMOVIRUS F PROTEIN; HUMAN METAPNEUMOVIRUS VACCINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIVE VACCINE; VIRUS ANTIBODY;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL CELL; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DISEASE SEVERITY; FEMALE; HEADACHE; HUMAN; HUMAN METAPNEUMOVIRUS; HUMAN METAPNEUMOVIRUS INFECTION; IMMUNOGENICITY; INOCULATION; MALE; NONHUMAN; NOSE SMEAR; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SYMPTOM; VIRUS CHARACTERIZATION; VIRUS DETECTION; VIRUS INFECTIVITY; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS SHEDDING; WILD TYPE; ANIMAL; BIOSYNTHESIS; BLOOD; CHALLENGE; GENETICS; IMMUNOLOGY; METAPNEUMOVIRUS; PARAMYXOVIRUS INFECTION; RESPIRATORY TRACT INFECTION; VIROLOGY; VIRUS LOAD; CLINICAL TRIAL; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS;

CHALLENGE; HMPV; HUMAN METAPNEUMOVIRUS;

ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CYTOKINES; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; METAPNEUMOVIRUS; PARAMYXOVIRIDAE INFECTIONS; RESPIRATORY TRACT INFECTIONS; VACCINES, ATTENUATED; VIRAL LOAD; VIRAL VACCINES; VIRUS SHEDDING;

EID: 84888592446     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jit356     Document Type: Article

References (42)

1. van den Hoogen BG, de Jong JC, Groen J, et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med 2001; 7:719-24.
2. Esper F, Boucher D, Weibel C, Martinello RA, Kahn JS. Human metapneumovirus infection in the United States: clinical manifestations associated with a newly emerging respiratory infection in children. Pediatrics 2003; 111:1407-10.
3. Freymouth F, Vabret A, Legrand L, et al. Presence of the new human metapneumovirus in French children with bronchiolitis. Pediatr Infect Dis J 2003; 22:92-4.
4. Stockton J, Stephenson I, Fleming D, Zambon M. Human metapneumovirus as a cause of community-acquired respiratory illness. Emerg Infect Dis 2002; 8:897-901.
5. Peiris JS, Tang WH, Chan KH, et al. Children with respiratory disease associated with metapneumovirus in Hong Kong. Emerg Infect Dis 2003; 9:628-33.
6. Madhi SA, Ludewick H, Kuwanda L, van Niekerk N, Cutland C, Klugman KP. Seasonality, incidence, and repeat human metapneumovirus lower respiratory tract infections in an area with a high prevalence of human immunodeficiency virus type-1 infection. Pediatr Infect Dis J 2007; 26:693-9.
7. Kroll JL, Weinberg A. Human metapneumovirus. Semin Respir Crit Care Med 2011; 32:447-53.
8. Ebihara T, Endo R, Kikuta H, Ishiguro N, Ishiko H, Kobayashi K. Comparison of the seroprevalence of human metapneumovirus and human respiratory syncytial virus. J Med Virol 2004; 72:304-6.
9. Wolf DG, Zakay-Rones Z, Fadeela A, Greenberg D, Dagan R. High seroprevalence of human metapneumovirus among young children in Israel. J Infect Dis 2003; 188:1865-7.
10. Falsey AR. Human metapneumovirus infection in adults. Pediatr Infect Dis J 2008; 27:S80-3.
11. Walsh EE, Peterson DR, Falsey AR. Human metapneumovirus infections in adults: Another piece of the puzzle. Arch Intern Med 2008; 168:2489-96.
12. Williams JV, Crowe JE Jr., Enriquez R, et al. Human metapneumovirus infection plays an etiologic role in acute asthma exacerbations requiring hospitalization in adults. J Infect Dis 2005; 192:1149-53.
13. Deffrasnes C, Hamelin ME, Boivin G. Human metapneumovirus. Semin Respir Crit Care Med 2007; 28:213-21.
14. Williams JV, Harris PA, Tollefson SJ, et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med 2004; 350:443-50.
15. Esper F, Martinello RA, Boucher D, et al. A 1-year experience with human metapneumovirus in children aged <5 years. J Infect Dis 2004; 189:1388-96.
16. Kahn JS. Epidemiology of human metapneumovirus. Clin Microbiol Rev 2006; 19:546-57.
17. Gaunt ER, Harvala H, McIntyre C, Templeton KE, Simmonds P. Disease burden of the most commonly detected respiratory viruses in hospitalized patients calculated using the disability adjusted life year (DALY) model. J Clin Virol 2011; 52:215-21.
18. Buchholz UJ, Nagashima K, Murphy BR, Collins PL. Live vaccines for human metapneumovirus designed by reverse genetics. Expert Rev Vaccines 2006; 5:695-706.
19. Herfst S, Fouchier RA. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections. J Clin Virol 2008; 41:49-52.
20. Karron RA, Wright PF, Belshe RB, et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005; 191:1093-104.
21. Wright PF, Karron RA, Belshe RB, et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000; 182:1331-42.
22. Greenberg DP, Walker RE, Lee MS, et al. A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy. J Infect Dis 2005; 191:1116-22.
23. Karron RA, Steinhoff MC, Subbarao EK, et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995; 14:10-6.
24. Biacchesi S, Murphy BR, Collins PL, Buchholz UJ. Frequent frameshift and point mutations in the SH gene of human metapneumovirus passaged in vitro. J Virol 2007; 81:6057-67.
25. Peret TC, Boivin G, Li Y, et al. Characterization of human metapneumoviruses isolated from patients in North America. J Infect Dis 2002; 185:1660-3.
26. Biacchesi S, Skiadopoulos MH, Tran KC, Murphy BR, Collins PL, Buchholz UJ. Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology 2004; 321:247-59.
27. Karron RA, Callahan K, Luke C, et al. A Live Attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis 2009; 199:711-6.
28. Karron RA, Talaat K, Luke C, et al. Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine 2009; 27:4953-60.
29. Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009; 27:3744-53.
30. Talaat KR, Karron RA, Liang PH, et al. An open-label phase I trial of a live attenuated H2N2 influenza virus vaccine in healthy adults. Influenza Other Respi Viruses 2013; 7:66-73.
31. Talaat KR, Karron RA, Luke CJ, et al. An open label phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adults. Vaccine 2011; 29:3144-8.
32. Coates HV, Alling DW, Chanock RM. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966; 83:299-313.
33. Richman DD, Murphy BR, Tierney EL, Chanock RM. Specificity of the local secretory antibody to influenza A virus infection. J Immunol 1974; 113:1654-6.
34. Murphy BR, Nelson DL, Wright PF, Tierney EL, Phelan MA, Chanock RM. Secretory and systemic immunological response in children infected with live attenuated influenza A virus vaccines. Infect Immun 1982; 36:1102-8.
35. Dabitao D, Margolick JB, Lopez J, Bream JH. Multiplex measurement of proinflammatory cytokines in human serum: comparison of the Meso Scale Discovery electrochemiluminescence assay and the cytometric bead array. J Immunol Methods 2011; 372:71-7.
36. Clements ML, Belshe RB, King J, et al. Evaluation of bovine, coldadapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991; 29: 1175-82.
37. Lee FE, Walsh EE, Falsey AR, Betts RF, Treanor JJ. Experimental infection of humans with A2 respiratory syncytial virus. Antiviral Res 2004; 63:191-6.
38. Biacchesi S, Pham QN, Skiadopoulos MH, Murphy BR, Collins PL, Buchholz UJ. Infection of nonhuman primates with recombinant human metapneumovirus lacking the SH, G, or M2-2 protein categorizes each as a nonessential accessory protein and identifies vaccine candidates. J Virol 2005; 79:12608-13.
39. Kim S, Sung H, Im HJ, Hong SJ, Kim MN. Molecular epidemiological investigation of a nosocomial outbreak of human metapneumovirus infection in a pediatric hemato-oncology patient population. J Clin Microbiol 2009; 47:1221-4.
40. Te Wierik MJ, Nguyen DT, Beersma MF, Thijsen SF, Heemstra KA. An outbreak of severe respiratory tract infection caused by human metapneumovirus in a residential care facility for elderly in Utrecht, the Netherlands, January to March 2010. Euro Surveill 2012; 17:20132.
41. Darniot M, Petrella T, Aho S, Pothier P, Manoha C. Immune response and alteration of pulmonary function after primary human metapneumovirus (hMPV) infection of BALB/c mice. Vaccine 2005; 23: 4473-80.
42. Laham FR, Israele V, Casellas JM, et al. Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis 2004; 189:2047-56.